Conjunctivoplasty: Surgical Reconstruction of the Conjunctiva — Cost, Top Hospitals & Success Rates | MyMedicPlus

Conjunctivoplasty is a broad term encompassing surgical procedures that reconstruct, repair, or augment the conjunctiva — the thin, transparent mucous membrane that lines the inner surfaces of the eyelids (palpebral conjunctiva) and covers the white of the eye (bulbar conjunctiva) up to the corneoscleral limbus. The conjunctiva plays a critical role in maintaining the ocular surface tear film, protecting the underlying sclera and cornea, and contributing to ocular immune defence. When the conjunctiva is destroyed by trauma, chemical burns, disease, or surgical excision, its restoration is essential to preserve vision, comfort, and eye health.

The procedure encompasses a range of surgical techniques depending on the underlying cause, the size and location of the conjunctival defect, and whether the limbal stem cells (cells that renew the corneal and conjunctival epithelium) are involved. Common techniques include conjunctival autograft (using the patient's own superior bulbar conjunctiva as donor tissue), amniotic membrane transplantation (using preserved human amniotic membrane as a biological scaffold), and oral mucous membrane grafting for extensive ocular surface disease. Adjunctive agents such as mitomycin C (an anti-metabolite) are used in pterygium surgery to reduce recurrence rates.

Conjunctivoplasty is increasingly available as a high-quality, cost-effective procedure in medical tourism destinations across Asia and Eastern Europe, where experienced ophthalmic surgeons at accredited eye hospitals offer international patients access to advanced ocular surface surgery at substantially lower cost than in the United States, United Kingdom, or Australia.

Conjunctivoplasty addresses the following conditions requiring conjunctival reconstruction or repair:

• Pterygium: A fleshy, fibrovascular growth of the conjunctiva that encroaches onto the cornea, typically from the nasal side; causes redness, irritation, tearing, and — if large — distortion of vision (irregular astigmatism) or corneal scarring. Surgical excision with conjunctival autograft is the gold-standard treatment.
• Symblepharon: Pathological adhesions between the palpebral and bulbar conjunctiva; results from chemical (alkali/acid) burns, thermal injury, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), ocular cicatricial pemphigoid, or prior ocular surgery. Causes restricted eye movement, diplopia, lagophthalmos, and chronic ocular surface failure.
• Conjunctival tumours: Benign (conjunctival naevi, dermoids, papillomas, granulomas) and malignant (ocular surface squamous neoplasia/OSSN, conjunctival melanoma) lesions requiring excision with conjunctival reconstruction of the defect.
• Conjunctival scarring from trachoma: Chronic bacterial infection (Chlamydia trachomatis) causing progressive cicatricial changes leading to trichiasis and corneal blindness; reconstructive surgery is part of WHO-recommended trachoma control strategies.
• Pinguecula: Yellow-white conjunctival deposits at the limbus causing cosmetic concern or significant irritation; surgical excision with conjunctivoplasty for large or symptomatic lesions.
• Conjunctival defects after trauma or surgery: Bare sclera defects following tumour excision, trauma, or filtering bleb-related complications (bleb revision) require reconstruction to prevent scleral melting and infection.
• Ocular cicatricial diseases: Mucous membrane pemphigoid, SJS/TEN sequelae, and graft-versus-host disease (GVHD) causing progressive conjunctival scarring requiring amniotic membrane or oral mucous membrane graft reconstruction.

Candidacy for conjunctivoplasty is determined by an ophthalmologist — specifically an anterior segment or corneal specialist — following slit-lamp examination and, for conjunctival tumours, diagnostic biopsy. Key considerations include:

• Pterygium patients: Surgery is recommended when the pterygium causes significant visual disturbance (>1–2 mm corneal encroachment), induces significant astigmatism, or causes persistent symptoms (redness, irritation) unresponsive to lubricant drops. Cosmesis alone is an accepted indication. Surgery is delayed until the pterygium is 'quiet' (not actively inflamed) where possible.
• Symblepharon patients: Surgical release is indicated when adhesions restrict eye movement, cause diplopia, interfere with lid closure (lagophthalmos and exposure keratopathy), or significantly impair quality of life. Underlying cicatricial disease must be quiescent before surgery to reduce recurrence risk.
• Conjunctival tumour patients: Surgical excision is indicated for growing, symptomatic, or histologically confirmed malignant lesions; OSSN lesions are increasingly managed with topical mitomycin C or 5-fluorouracil as primary or adjunct therapy.
• General fitness: Most conjunctivoplasty procedures are performed under local anaesthesia (periocular block with or without sedation) and are suitable for medically complex patients who cannot tolerate general anaesthesia.
• Exclusions and cautions: Active ocular inflammation should be controlled before elective surgery; patients on systemic anticoagulants require medication management; contact lens wearers must discontinue lens use before and after surgery as advised by their surgeon.

The surgical technique for conjunctivoplasty is tailored to the specific condition, defect size, and availability of donor tissue:

• Conjunctival autograft (CAG): The gold standard for pterygium excision. After removal of the pterygium, a free graft of conjunctiva is harvested from the superior bulbar conjunctiva of the same eye under the upper lid (where it is cosmetically hidden) and transposed to cover the bare sclera defect at the excision site. Graft attachment is achieved with fibrin tissue glue (cyanoacrylate or fibrin-based) or absorbable sutures. Fibrin glue significantly reduces operative time, post-operative discomfort, and suture-related complications compared to sutures. Recurrence rate with CAG is 5–10%, compared to 30–80% with bare sclera excision alone.
• Amniotic membrane transplantation (AMT): Preserved human amniotic membrane (the innermost layer of the placenta) is applied as a biological scaffold to reconstruct large conjunctival defects where autograft tissue is insufficient, or to promote re-epithelialisation of the ocular surface in acute chemical burns (emergency AMT), symblepharon release, or OSSN defects. Amniotic membrane has anti-inflammatory, anti-fibrotic, and pro-epithelialisation properties. It can be applied as an onlay graft (epithelial side up, acting as a basement membrane substitute) or inlay graft (basement membrane side up, for larger surface coverage).
• Oral mucous membrane graft (OMMG): For extensive bilateral cicatricial conjunctival disease (SJS/TEN sequelae, mucous membrane pemphigoid) where the fornices and palpebral conjunctiva require reconstruction, oral mucosa (from the inner cheek or labial mucosa) provides an analogous non-keratinising mucosal lining similar to conjunctiva. Complex procedure usually requiring general anaesthesia.
• Mitomycin C (MMC) augmentation: Intraoperative application of topical MMC (0.02–0.04%) to the bare sclera for 2–5 minutes prior to graft placement in pterygium surgery significantly reduces recurrence rates by inhibiting subconjunctival fibroblast proliferation. MMC is particularly useful for recurrent pterygia where autograft alone carries higher recurrence rates.
• Limbal stem cell transplant (conjunctival limbal autograft / allograft): For limbal stem cell deficiency from chemical burns, Stevens-Johnson syndrome, or aniridia, a combined procedure involving transplantation of limbal tissue with conjunctiva is required to restore the corneal epithelial renewal capacity.

Conjunctivoplasty delivers measurable functional and cosmetic improvements:

• Pterygium recurrence rates of 5–10%: Conjunctival autograft with fibrin glue achieves the lowest recurrence rates of any pterygium surgical technique, with long-term remission in the majority of patients
• Restoration of comfortable vision: Pterygium excision corrects corneal astigmatism induced by the lesion, improving best-corrected visual acuity and reducing glare and distortion
• Resolution of chronic ocular surface discomfort: The majority of patients with pterygium or pinguecula experience significant relief from foreign body sensation, redness, and tearing after surgery
• Improved eye movement and alignment: Release of symblepharon adhesions restores ocular motility, eliminates diplopia in many cases, and allows eyelid closure to protect the cornea
• Tumour control: Surgical excision of OSSN and conjunctival melanoma provides definitive local therapy and tissue for complete histological staging; adjunctive topical chemotherapy or cryotherapy is used for involved margins
• Cosmetic improvement: Removal of a prominent red pterygium or pinguecula substantially improves the cosmetic appearance of the eye — an important quality-of-life benefit for many patients
• Short recovery and excellent tolerability: Most procedures under local anaesthesia are well-tolerated with minimal post-operative downtime; day surgery is standard

Conjunctivoplasty is generally safe, but recognised risks include:

• Pterygium recurrence: Even with conjunctival autograft, recurrence rates of 5–15% exist, particularly in young patients, those living in high UV exposure regions, and those with highly vascular primary pterygia; recurrent pterygia are more aggressive and harder to excise secondarily
• Graft complications: Graft retraction or dehiscence (early loss of graft position), graft necrosis, and graft hypertrophy (Tenon's capsule cyst); more common with suture fixation than fibrin glue; requires early identification and re-fixation or repeat grafting
• Mitomycin C toxicity: Overuse of MMC or poor technique can cause scleral melting (necrotising scleritis), corneal epithelial toxicity, and delayed tear film instability; careful dosing and application technique are critical
• Diplopia: Damage to underlying extraocular muscle (particularly medial rectus near the nasal pterygium excision zone) during surgery can cause temporary or permanent diplopia; rare in experienced hands
• Corneal dellen: A localised area of corneal thinning adjacent to the graft edge from tear film inadequacy; typically responds to intensive lubricant eye drops
• Infection: Bacterial conjunctivitis or keratitis post-surgery; risk minimised with prophylactic topical antibiotic drops
• Symblepharon reformation: In patients with underlying cicatricial disease (SJS, MMP), reconstructed conjunctiva may re-scar; ongoing topical immunosuppression and rigorous follow-up are essential
• Subconjunctival haemorrhage: Common, self-resolving redness after surgery; not harmful

Recovery from conjunctivoplasty follows a predictable timeline that varies slightly by procedure complexity:

• Immediately post-operatively: A pad and shield are placed over the operated eye and removed at 24 hours (or by the patient the following morning); some surgeons keep the pad for 24 hours after pterygium surgery with fibrin glue
• First week: Topical antibiotic and steroid eye drops are prescribed — typically 4 times daily; the operated eye may feel gritty, watery, and photosensitive; mild swelling of the lids and conjunctiva (chemosis) is normal and resolves over 1–2 weeks
• Suture management: If absorbable sutures are used, they dissolve over 2–4 weeks; non-absorbable sutures (rarely used) require planned removal at the slit lamp; fibrin glue does not require suture removal
• Weeks 2–4: Gradual return of comfortable vision as the graft settles and surface epithelialisation is complete; contact lens use may resume after the surface is fully healed, typically at 6–8 weeks
• Sun protection: UV-protective sunglasses with side shields are strongly recommended post-operatively and long-term to reduce pterygium recurrence risk (UV exposure is the primary aetiological factor)
• Activity restrictions: Avoid rubbing the eye, dusty environments, and swimming for 4 weeks; most desk activities can resume within a few days; driving depends on operated-eye visual acuity and local regulations
• Follow-up schedule: Day 1, week 1, month 1, month 3, and month 12 — with additional visits as clinically indicated; pterygium patients are followed for at least 12 months to identify early recurrence, which is most effectively treated promptly

Conjunctivoplasty costs vary substantially by country, technique, and clinical complexity:

• United States: $1,500–$4,000 for pterygium excision with conjunctival autograft; $3,000–$8,000 for complex amniotic membrane transplant or OSSN excision; ophthalmology fees, operating facility, and anaesthesia billed separately
• United Kingdom (private): £1,000–£2,500 for pterygium surgery; NHS provision for symptomatic cases; complex reconstruction £2,500–£6,000
• India: $200–$600 for pterygium surgery with autograft at NABH/NABL-accredited eye hospitals; $500–$1,500 for amniotic membrane transplant — representing savings of 70–85% vs. US pricing; major centres include LV Prasad Eye Institute, Sankara Nethralaya, AIIMS
• Thailand: $500–$1,500 for pterygium surgery; $1,000–$3,000 for complex conjunctival reconstruction; excellent ophthalmic centres in Bangkok
• Turkey: $400–$1,200 for pterygium surgery; $800–$2,500 for advanced reconstruction; major eye hospitals in Istanbul and Ankara
• Key cost determinants:
  • Type of technique: CAG (lower cost) vs. AMT (amniotic membrane additional cost) vs. OMMG (higher complexity)
  • Use of fibrin glue vs. sutures (glue adds material cost but reduces operative time)
  • Adjunctive MMC use
  • Primary vs. recurrent pterygium (recurrent cases are longer and more technically demanding)
  • General vs. local anaesthesia

The following non-surgical and minimally invasive alternatives are available depending on the specific condition:

• Lubricant and anti-inflammatory eye drops (for pterygium/pinguecula): Preservative-free artificial tear drops, topical NSAIDs, and short courses of topical steroids relieve symptoms of irritation and redness but do not reduce the size of a pterygium or halt its growth; appropriate for small asymptomatic lesions and mild symptoms
• UV-protective eyewear: Wraparound sunglasses with side shields and UV400 protection reduce pterygium growth and are recommended both for prevention in high-risk individuals (outdoor workers, those living near the equator) and post-operatively to reduce recurrence
• Topical immunosuppressive chemotherapy (for OSSN): Topical mitomycin C (0.04%), 5-fluorouracil (1%), or interferon alpha-2b drops as primary treatment for low-stage ocular surface squamous neoplasia avoid the need for excisional surgery in select cases; complete clinical response rates of 70–95% reported but require prolonged treatment courses and close monitoring
• Punctal occlusion (for dry eye in cicatricial conjunctival disease): Silicone plugs inserted into the tear duct puncta conserve natural tears and are an adjunct (not substitute) for conjunctivoplasty in managing ocular surface dryness from scarring
• Scleral contact lenses: Large-diameter contact lenses that vault over the cornea and rest on the scleral conjunctiva, creating a liquid reservoir over the ocular surface; invaluable for managing irregular corneal surfaces and severe dry eye in SJS or chemical burn patients who cannot undergo or are awaiting reconstructive surgery
• Cryotherapy: Application of cryoprobe to the conjunctival surface for treatment of conjunctival dysplasia (OSSN) at surgical margins or as primary treatment in thin, superficial lesions; often combined with excision